IDENTIFICATION OF DIAGNOSTIC BIOMARKERS AND THERAPEUTIC AGENTS FOR ALS

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 长期目标是通过发现ALS的代谢组学和蛋白质组学生物标志物来研究ALS的发病机制。研究假设为：1）ALS患者存在持久的生化变化，并且可以在血浆和脑脊液（CSF）中检测到。2)这些生物化学特征是ALS所特有的，与其他神经系统疾病和对照受试者中发现的生物化学特征不同。3)代谢组学和蛋白质组学的分析将为ALS提供生物标志物并揭示疾病机制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The long-term goal is to study the pathogenesis of ALS by discovering metabolomic and proteomic biomarkers for this disease. The study hypotheses are that: 1) There are biochemical changes in ALS patients that are long lasting and that can be picked up in the plasma and cerebrospinal fluid (CSF). 2) These biochemical signatures are unique to ALS and are distinct from those found in other neurological disorders and from control subjects. 3) Analysis of the metabolome and proteome will provide biomarkers for ALS and disclose disease mechanisms.